Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 444

1.

Reduced Terminal Complement Complex Formation in Mice Manifests in Low Bone Mass and Impaired Fracture Healing.

Mödinger Y, Rapp AE, Vikman A, Ren Z, Fischer V, Bergdolt S, Haffner-Luntzer M, Song WC, Lambris JD, Huber-Lang M, Neidlinger-Wilke C, Brenner R, Ignatius A.

Am J Pathol. 2018 Oct 17. pii: S0002-9440(18)30398-5. doi: 10.1016/j.ajpath.2018.09.011. [Epub ahead of print]

2.

Complement C5a-Mediated TAM-ing of Antitumor Immunity Drives Squamous Carcinogenesis.

Mastellos DC, Reis ES, Lambris JD.

Cancer Cell. 2018 Oct 8;34(4):531-533. doi: 10.1016/j.ccell.2018.09.005.

PMID:
30300576
3.

Short Leucine-Rich Proteoglycans Modulate Complement Activity and Increase Killing of the Respiratory Pathogen Moraxella catarrhalis.

Laabei M, Liu G, Ermert D, Lambris JD, Riesbeck K, Blom AM.

J Immunol. 2018 Nov 1;201(9):2721-2730. doi: 10.4049/jimmunol.1800734. Epub 2018 Sep 28.

PMID:
30266767
4.

Safety profile after prolonged C3 inhibition.

Reis ES, Berger N, Wang X, Koutsogiannaki S, Doot RK, Gumas JT, Foukas PG, Resuello RRG, Tuplano JV, Kukis D, Tarantal AF, Young AJ, Kajikawa T, Soulika AM, Mastellos DC, Yancopoulou D, Biglarnia AR, Huber-Lang M, Hajishengallis G, Nilsson B, Lambris JD.

Clin Immunol. 2018 Sep 20;197:96-106. doi: 10.1016/j.clim.2018.09.004. [Epub ahead of print]

PMID:
30217791
5.

Gingival Exudatome Dynamics Implicate Inhibition of the Alternative Complement Pathway in the Protective Action of the C3 Inhibitor Cp40 in Nonhuman Primate Periodontitis.

Bostanci N, Bao K, Li X, Maekawa T, Grossmann J, Panse C, Briones RA, Resuello RRG, Tuplano JV, Garcia CAG, Reis ES, Lambris JD, Hajishengallis G.

J Proteome Res. 2018 Sep 7;17(9):3153-3175. doi: 10.1021/acs.jproteome.8b00263. Epub 2018 Aug 29.

PMID:
30111112
6.

Expanding Complement Therapeutics for the Treatment of Paroxysmal Nocturnal Hemoglobinuria.

Mastellos DC, Reis ES, Yancopoulou D, Risitano AM, Lambris JD.

Semin Hematol. 2018 Jul;55(3):167-175. doi: 10.1053/j.seminhematol.2018.02.002. Epub 2018 Feb 14. Review.

PMID:
30032754
7.

Novel Immunoassay for Complement Activation by PF4/Heparin Complexes.

Khandelwal S, Johnson AM, Liu J, Keire D, Sommers C, Ravi J, Lee GM, Lambris JD, Reis ES, Arepally GM.

Thromb Haemost. 2018 Aug;118(8):1484-1487. doi: 10.1055/s-0038-1660858. Epub 2018 Jun 30. No abstract available.

PMID:
29960275
8.

New Analogs of the Complement C3 Inhibitor Compstatin with Increased Solubility and Improved Pharmacokinetic Profile.

Berger N, Alayi TD, Resuello RRG, Tuplano JV, Reis ES, Lambris JD.

J Med Chem. 2018 Jul 26;61(14):6153-6162. doi: 10.1021/acs.jmedchem.8b00560. Epub 2018 Jul 3.

PMID:
29920096
9.

Functional Relevance of the Anaphylatoxin Receptor C3aR for Platelet Function and Arterial Thrombus Formation Marks an Intersection Point Between Innate Immunity and Thrombosis.

Sauter RJ, Sauter M, Reis ES, Emschermann FN, Nording H, Ebenhöch S, Kraft P, Münzer P, Mauler M, Rheinlaender J, Madlung J, Edlich F, Schäffer TE, Meuth SG, Dürschmied D, Geisler T, Borst O, Gawaz M, Kleinschnitz C, Lambris JD, Langer HF.

Circulation. 2018 Oct 16;138(16):1720-1735. doi: 10.1161/CIRCULATIONAHA.118.034600.

PMID:
29802205
10.

Innate immune responses to trauma.

Huber-Lang M, Lambris JD, Ward PA.

Nat Immunol. 2018 Apr;19(4):327-341. doi: 10.1038/s41590-018-0064-8. Epub 2018 Mar 5. Review.

11.

The Complement System Is Critical in Maintaining Retinal Integrity during Aging.

Mukai R, Okunuki Y, Husain D, Kim CB, Lambris JD, Connor KM.

Front Aging Neurosci. 2018 Feb 15;10:15. doi: 10.3389/fnagi.2018.00015. eCollection 2018.

12.

Protective Effects of the Complement Inhibitor Compstatin CP40 in Hemorrhagic Shock.

van Griensven M, Ricklin D, Denk S, Halbgebauer R, Braun CK, Schultze A, Hönes F, Koutsogiannaki S, Primikyri A, Reis E, Messerer D, Hafner S, Radermacher P, Biglarnia AR, Resuello RRG, Tuplano JV, Mayer B, Nilsson K, Nilsson B, Lambris JD, Huber-Lang M.

Shock. 2018 Feb 14. doi: 10.1097/SHK.0000000000001127. [Epub ahead of print]

PMID:
29461464
13.

Factor H C-Terminal Domains Are Critical for Regulation of Platelet/Granulocyte Aggregate Formation.

Blatt AZ, Saggu G, Cortes C, Herbert AP, Kavanagh D, Ricklin D, Lambris JD, Ferreira VP.

Front Immunol. 2017 Nov 23;8:1586. doi: 10.3389/fimmu.2017.01586. eCollection 2017.

14.

The renaissance of complement therapeutics.

Ricklin D, Mastellos DC, Reis ES, Lambris JD.

Nat Rev Nephrol. 2018 Jan;14(1):26-47. doi: 10.1038/nrneph.2017.156. Epub 2017 Dec 4. Review.

15.

Novel mechanisms and functions of complement.

Hajishengallis G, Reis ES, Mastellos DC, Ricklin D, Lambris JD.

Nat Immunol. 2017 Nov 16;18(12):1288-1298. doi: 10.1038/ni.3858. Review.

PMID:
29144501
16.

Complement Activation via a C3a Receptor Pathway Alters CD4+ T Lymphocytes and Mediates Lung Cancer Progression.

Kwak JW, Laskowski J, Li HY, McSharry MV, Sippel TR, Bullock BL, Johnson AM, Poczobutt JM, Neuwelt AJ, Malkoski SP, Weiser-Evans MC, Lambris JD, Clambey ET, Thurman JM, Nemenoff RA.

Cancer Res. 2018 Jan 1;78(1):143-156. doi: 10.1158/0008-5472.CAN-17-0240. Epub 2017 Nov 8.

PMID:
29118090
17.

Factor H-IgG Chimeric Proteins as a Therapeutic Approach against the Gram-Positive Bacterial Pathogen Streptococcus pyogenes.

Blom AM, Magda M, Kohl L, Shaughnessy J, Lambris JD, Ram S, Ermert D.

J Immunol. 2017 Dec 1;199(11):3828-3839. doi: 10.4049/jimmunol.1700426. Epub 2017 Oct 30.

PMID:
29084837
18.

Complement receptors C5aR1 and C5aR2 act differentially during the early immune response after bone fracture but are similarly involved in bone repair.

Kovtun A, Bergdolt S, Hägele Y, Matthes R, Lambris JD, Huber-Lang M, Ignatius A.

Sci Rep. 2017 Oct 25;7(1):14061. doi: 10.1038/s41598-017-14444-3.

19.

Complement-activation fragment C4a mediates effector functions by binding as untethered agonist to protease-activated receptors 1 and 4.

Wang H, Ricklin D, Lambris JD.

Proc Natl Acad Sci U S A. 2017 Oct 10;114(41):10948-10953. doi: 10.1073/pnas.1707364114. Epub 2017 Sep 26.

20.

Local endothelial complement activation reverses endothelial quiescence, enabling t-cell homing, and tumor control during t-cell immunotherapy.

Facciabene A, De Sanctis F, Pierini S, Reis ES, Balint K, Facciponte J, Rueter J, Kagabu M, Magotti P, Lanitis E, DeAngelis RA, Buckanovich RJ, Song WC, Lambris JD, Coukos G.

Oncoimmunology. 2017 Jun 8;6(9):e1326442. doi: 10.1080/2162402X.2017.1326442. eCollection 2017.

21.

Complement in cancer: untangling an intricate relationship.

Reis ES, Mastellos DC, Ricklin D, Mantovani A, Lambris JD.

Nat Rev Immunol. 2018 Jan;18(1):5-18. doi: 10.1038/nri.2017.97. Epub 2017 Sep 18. Review.

22.

Safety and Efficacy of the Complement Inhibitor AMY-101 in a Natural Model of Periodontitis in Non-human Primates.

Kajikawa T, Briones RA, Resuello RRG, Tuplano JV, Reis ES, Hajishengallis E, Garcia CAG, Yancopoulou D, Lambris JD, Hajishengallis G.

Mol Ther Methods Clin Dev. 2017 Aug 18;6:207-215. doi: 10.1016/j.omtm.2017.08.001. eCollection 2017 Sep 15.

23.

Porphyromonas gingivalis disturbs host-commensal homeostasis by changing complement function.

Olsen I, Lambris JD, Hajishengallis G.

J Oral Microbiol. 2017 Jun 30;9(1):1340085. doi: 10.1080/20002297.2017.1340085. eCollection 2017. Review.

24.

Complement C5a-Induced Changes in Neutrophil Morphology During Inflammation.

Denk S, Taylor RP, Wiegner R, Cook EM, Lindorfer MA, Pfeiffer K, Paschke S, Eiseler T, Weiss M, Barth E, Lambris JD, Kalbitz M, Martin T, Barth H, Messerer DAC, Gebhard F, Huber-Lang MS.

Scand J Immunol. 2017 Sep;86(3):143-155. doi: 10.1111/sji.12580.

25.

Regulator-dependent mechanisms of C3b processing by factor I allow differentiation of immune responses.

Xue X, Wu J, Ricklin D, Forneris F, Di Crescenzio P, Schmidt CQ, Granneman J, Sharp TH, Lambris JD, Gros P.

Nat Struct Mol Biol. 2017 Aug;24(8):643-651. doi: 10.1038/nsmb.3427. Epub 2017 Jul 3.

26.

Iron oxide nanoparticles induce cytokine secretion in a complement-dependent manner in a human whole blood model.

Wolf-Grosse S, Rokstad AM, Ali S, Lambris JD, Mollnes TE, Nilsen AM, Stenvik J.

Int J Nanomedicine. 2017 May 23;12:3927-3940. doi: 10.2147/IJN.S136453. eCollection 2017.

27.

Alginate microbeads are coagulation compatible, while alginate microcapsules activate coagulation secondary to complement or directly through FXII.

Gravastrand C, Hamad S, Fure H, Steinkjer B, Ryan L, Oberholzer J, Lambris JD, Lacík I, Mollnes TE, Espevik T, Brekke OL, Rokstad AM.

Acta Biomater. 2017 Aug;58:158-167. doi: 10.1016/j.actbio.2017.05.052. Epub 2017 May 30.

28.

Complement component C3aR constitutes a novel regulator for chick eye morphogenesis.

Grajales-Esquivel E, Luz-Madrigal A, Bierly J, Haynes T, Reis ES, Han Z, Gutierrez C, McKinney Z, Tzekou A, Lambris JD, Tsonis PA, Del Rio-Tsonis K.

Dev Biol. 2017 Aug 1;428(1):88-100. doi: 10.1016/j.ydbio.2017.05.019. Epub 2017 May 30.

29.

Complement C5a Functions as a Master Switch for the pH Balance in Neutrophils Exerting Fundamental Immunometabolic Effects.

Denk S, Neher MD, Messerer DAC, Wiegner R, Nilsson B, Rittirsch D, Nilsson-Ekdahl K, Weckbach S, Ignatius A, Kalbitz M, Gebhard F, Weiss ME, Vogt J, Radermacher P, Köhl J, Lambris JD, Huber-Lang MS.

J Immunol. 2017 Jun 15;198(12):4846-4854. doi: 10.4049/jimmunol.1700393. Epub 2017 May 10.

30.

Complement C3-Targeted Therapy: Replacing Long-Held Assertions with Evidence-Based Discovery.

Mastellos DC, Reis ES, Ricklin D, Smith RJ, Lambris JD.

Trends Immunol. 2017 Jun;38(6):383-394. doi: 10.1016/j.it.2017.03.003. Epub 2017 Apr 14.

31.

Coarse-Grained Conformational Sampling of Protein Structure Improves the Fit to Experimental Hydrogen-Exchange Data.

Devaurs D, Antunes DA, Papanastasiou M, Moll M, Ricklin D, Lambris JD, Kavraki LE.

Front Mol Biosci. 2017 Mar 10;4:13. doi: 10.3389/fmolb.2017.00013. eCollection 2017.

32.

Structural Implications for the Formation and Function of the Complement Effector Protein iC3b.

Papanastasiou M, Koutsogiannaki S, Sarigiannis Y, Geisbrecht BV, Ricklin D, Lambris JD.

J Immunol. 2017 Apr 15;198(8):3326-3335. doi: 10.4049/jimmunol.1601864. Epub 2017 Mar 3.

33.

Pericytes and immune cells contribute to complement activation in tubulointerstitial fibrosis.

Xavier S, Sahu RK, Landes SG, Yu J, Taylor RP, Ayyadevara S, Megyesi J, Stallcup WB, Duffield JS, Reis ES, Lambris JD, Portilla D.

Am J Physiol Renal Physiol. 2017 Mar 1;312(3):F516-F532. doi: 10.1152/ajprenal.00604.2016. Epub 2017 Jan 4.

34.

Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation.

Harder MJ, Kuhn N, Schrezenmeier H, Höchsmann B, von Zabern I, Weinstock C, Simmet T, Ricklin D, Lambris JD, Skerra A, Anliker M, Schmidt CQ.

Blood. 2017 Feb 23;129(8):970-980. doi: 10.1182/blood-2016-08-732800. Epub 2016 Dec 27.

35.

Method development and validation for the quantitation of the complement inhibitor Cp40 in human and cynomolgus monkey plasma by UPLC-ESI-MS.

Primikyri A, Papanastasiou M, Sarigiannis Y, Koutsogiannaki S, Reis ES, Tuplano JV, Resuello RR, Nilsson B, Ricklin D, Lambris JD.

J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Jan 15;1041-1042:19-26. doi: 10.1016/j.jchromb.2016.12.004. Epub 2016 Dec 6.

36.

Complement inhibition enables tumor delivery of LCMV glycoprotein pseudotyped viruses in the presence of antiviral antibodies.

Evgin L, Ilkow CS, Bourgeois-Daigneault MC, de Souza CT, Stubbert L, Huh MS, Jennings VA, Marguerie M, Acuna SA, Keller BA, Lefebvre C, Falls T, Le Boeuf F, Auer RA, Lambris JD, McCart JA, Stojdl DF, Bell JC.

Mol Ther Oncolytics. 2016 Nov 16;3:16027. eCollection 2016.

37.

More than complementing Tolls: complement-Toll-like receptor synergy and crosstalk in innate immunity and inflammation.

Hajishengallis G, Lambris JD.

Immunol Rev. 2016 Nov;274(1):233-244. doi: 10.1111/imr.12467. Review.

38.

Complement component C3 - The "Swiss Army Knife" of innate immunity and host defense.

Ricklin D, Reis ES, Mastellos DC, Gros P, Lambris JD.

Immunol Rev. 2016 Nov;274(1):33-58. doi: 10.1111/imr.12500. Review.

39.

Preformed mediators of defense-Gatekeepers enter the spotlight.

Ricklin D, Lambris JD.

Immunol Rev. 2016 Nov;274(1):5-8. doi: 10.1111/imr.12497. No abstract available.

PMID:
27782322
40.

Protection of host cells by complement regulators.

Schmidt CQ, Lambris JD, Ricklin D.

Immunol Rev. 2016 Nov;274(1):152-171. doi: 10.1111/imr.12475. Review.

41.

Complement C3 inhibitor Cp40 attenuates xenoreactions in pig hearts perfused with human blood.

Abicht JM, Kourtzelis I, Reichart B, Koutsogiannaki S, Primikyri A, Lambris JD, Chavakis T, Holdt L, Kind A, Guethoff S, Mayr T.

Xenotransplantation. 2017 Jan;24(1). doi: 10.1111/xen.12262. Epub 2016 Sep 27.

42.

Compstatin Cp40 blocks hematin-mediated deposition of C3b fragments on erythrocytes: Implications for treatment of malarial anemia.

Lindorfer MA, Cook EM, Reis ES, Ricklin D, Risitano AM, Lambris JD, Taylor RP.

Clin Immunol. 2016 Oct;171:32-35. doi: 10.1016/j.clim.2016.08.017. Epub 2016 Aug 18.

43.

High-Fat Diet-Induced Complement Activation Mediates Intestinal Inflammation and Neoplasia, Independent of Obesity.

Doerner SK, Reis ES, Leung ES, Ko JS, Heaney JD, Berger NA, Lambris JD, Nadeau JH.

Mol Cancer Res. 2016 Oct;14(10):953-965. Epub 2016 Aug 17.

44.

Complement therapeutics.

Ricklin D, Lambris JD.

Semin Immunol. 2016 Jun;28(3):205-7. doi: 10.1016/j.smim.2016.07.001. No abstract available.

PMID:
27522923
45.

Systems Analysis of the Complement-Induced Priming Phase of Liver Regeneration.

Min JS, DeAngelis RA, Reis ES, Gupta S, Maurya MR, Evans C, Das A, Burant C, Lambris JD, Subramaniam S.

J Immunol. 2016 Sep 15;197(6):2500-8. doi: 10.4049/jimmunol.1600628. Epub 2016 Aug 10.

46.

From orphan drugs to adopted therapies: Advancing C3-targeted intervention to the clinical stage.

Mastellos DC, Reis ES, Yancopoulou D, Hajishengallis G, Ricklin D, Lambris JD.

Immunobiology. 2016 Oct;221(10):1046-57. doi: 10.1016/j.imbio.2016.06.013. Epub 2016 Jun 16. Review.

47.

New milestones ahead in complement-targeted therapy.

Ricklin D, Lambris JD.

Semin Immunol. 2016 Jun;28(3):208-22. doi: 10.1016/j.smim.2016.06.001. Epub 2016 Jun 16. Review.

48.

Complement in disease: a defence system turning offensive.

Ricklin D, Reis ES, Lambris JD.

Nat Rev Nephrol. 2016 Jul;12(7):383-401. doi: 10.1038/nrneph.2016.70. Epub 2016 May 23. Review.

49.

Properdin-Mediated C5a Production Enhances Stable Binding of Platelets to Granulocytes in Human Whole Blood.

Blatt AZ, Saggu G, Kulkarni KV, Cortes C, Thurman JM, Ricklin D, Lambris JD, Valenzuela JG, Ferreira VP.

J Immunol. 2016 Jun 1;196(11):4671-4680. doi: 10.4049/jimmunol.1600040. Epub 2016 Apr 25.

50.

Differential capacity for complement receptor-mediated immune evasion by Porphyromonas gingivalis depending on the type of innate leukocyte.

Hajishengallis G, Krauss JL, Jotwani R, Lambris JD.

Mol Oral Microbiol. 2017 Apr;32(2):154-165. doi: 10.1111/omi.12161. Epub 2016 May 18.

Supplemental Content

Loading ...
Support Center